2-Chloro-4-(trifluoromethyl)pyridine → (1S,4S)-tert-butyl 5-(4-(trifluoromethyl)pyridin-2-yl)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate

HRID 624

반응식

HRID 624 반응식
CC(C)(C)OC(=O)N1C[C@@H]2C[C@H]1CN2.FC(F)(F)c1ccnc(Cl)c1>CC(C)(C)[O-].Cc1ccccc1.O=C(/C=C/c1ccccc1)/C=C/c1ccccc1.O=C(/C=C/c1ccccc1)/C=C/c1ccccc1.O=C(/C=C/c1ccccc1)/C=C/c1ccccc1.[Na+].[Pd].[Pd].c1ccc(P(c2ccccc2)c2ccc3ccccc3c2-c2c(P(c3ccccc3)c3ccccc3)ccc3ccccc23)cc1>CC(C)(C)OC(=O)N1C[C@@H]2C[C@H]1CN2c1cc(C(F)(F)F)ccn1

참가 물질

7

반응 조건

온도
105 °C

실험 절차

A 2.0-5.0 mL microwave vial was charged with (1S,4S)-tert-butyl 2,5-diazabicyclo[2.2.1]heptane-2-carboxylate (200 mg, 1.01 mmol), rac-2,2'-Bis(diphenylphosphino)-1,1'-binaphthyl (62.8 mg, 0.10 mmol), Sodium tert-butoxide (116 mg, 1.21 mmol), 2-Chloro-4-(trifluoromethyl)pyridine (0.156 mL, 1.21 mmol) and a mixture of toluene (2.5 mL) and DMF (.5 mL). The reaction mixture was degassed for 10 minutes with nitrogen, and then Tris(dibenzylideneacetone)dipalladium(0) (46.2 mg, 0.05 mmol) was added. The reaction mixture was stirred at 105°C in an oil bath 12h. The solution was diluted with EtOAc and washed with saturated NaHCO3 solution, brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The crude material was loaded on a 24g silica gel column and purified on a Teledyne Isco instrument, eluting with 10% to 40% ethyl acetate in heptane to provide (1S,4S)-tert-butyl 5-(4-(trifluoromethyl)pyridin-2-yl)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate (254 mg, 73.3 %) as a solid. 1H NMR (400MHz ,CHLOROFORM-d) d 8.26 (d, J = 5.5 Hz, 1 H), 6.75 (d, J = 5.1 Hz, 1 H), 6.48 (s, 1 H), 4.99 - 4.83 (m, 1 H), 4.76 - 4.52 (m, 1 H), 3.56 (t, J = 8.4 Hz, 1 H), 3.49 - 3.32 (m, 3 H), 2.04 - 1.91 (m, 2 H), 1.45 (d, J = 18.0 Hz, 9 H); MS m/z 344.2 [M+H]+ (ESI).

출처 및 근거

ORD 기록
ord-1d6228eeae6e455c9c2acbb4c4aa8214
출처 데이터셋
750 AstraZeneca ELN dataset
원본 링크
출처 보기

연결된 노트

불러오는 중…